We discussed the potential of allogeneic therapies across oncology and non-oncology and featured insights on leading developers, therapeutic classes, and current targets. Additionally, our industry experts provided an overview of clinical market trends, regulatory landscapes, and strategic considerations to help stakeholders make informed decisions. Watch the recording now.
Speak with industry experts
What is Beacon Cell Therapy?
Beacon Cell Therapy sector-specific curated database includes trial and drug records for preclinical, active, approved, and discontinued:
- Receptor-engineered cell therapies such as CAR (chimeric antigen receptor) and TCR (T-cell receptor) therapies
- Other engineered or non-engineered immune cell therapies such as natural killer cells and regulatory T cells (Tregs)
- Stem cell-derived and iPSC-derived cell therapies such as immune cells, somatic cells (e.g. cardiomyocytes and retinal pigment cells) and precursor cells
Who are Hanson Wade Intelligence?
Outsource your competitive intelligence to Hanson Wade Intelligence and have our analysts support your market landscaping and competitive benchmarking.
Hanson Wade Intelligence are modality experts with multi-project experience in preclinical and clinical evaluation of ADCs, Cell and Gene Therapy, RNA, Protein Degraders and much more. With strong primary and secondary research skills, Hanson Wade Intelligence is ideally positioned to be your CI partner.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements